PATENT CLAIM ANALYSIS

Application Number: 16289280
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "341000"]

Abstract:
The present disclosure discusses salt forms of 4-cyano-N-[2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)pyridin-3-yl]-1H-imidazole-2-carboxamide.

Claim (Index 32):
A method of treating an autoimmune disease that is at least one of systemic lupus erythematosus, rheumatoid arthritis and other forms of inflammatory arthritis, psoriasis, Sjogren's syndrome, multiple sclerosis, or uveitis in a subject comprising administering a therapeutically effective amount of at least one salt form of  claim 1  to the subject.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 99.0
- Lexical Diversity: 1.10526
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15651829', '15651385', '14822366', '13801191', '16015626']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8004403758222473
- 35 USC 102 Novelty (BERT): 0.5562708023947349
- Combined Prediction Score: 0.7760234184794961
- Mean Citation Score: 343.474226
- Max Citation Score: 427.90027
- Similarity Product: 376.9099154861557

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test